Logo image of CANG

CANGO INC/KY - ADR (CANG) Stock Fundamental Analysis

USA - NYSE:CANG - US1375861036 - ADR

4.45 USD
-0.17 (-3.68%)
Last: 9/19/2025, 8:04:00 PM
4.45 USD
0 (0%)
After Hours: 9/19/2025, 8:04:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CANG. CANG was compared to 122 industry peers in the Specialty Retail industry. Both the profitability and financial health of CANG have multiple concerns. While showing a medium growth rate, CANG is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CANG was profitable.
The reported net income has been mixed in the past 5 years: CANG reported negative net income in multiple years.
In the past 5 years CANG reported 4 times negative operating cash flow.
CANG Yearly Net Income VS EBIT VS OCF VS FCFCANG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B 3B

1.2 Ratios

CANG has a Return On Assets (0.04%) which is comparable to the rest of the industry.
CANG has a Return On Equity (0.08%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA 0.04%
ROE 0.08%
ROIC N/A
ROA(3y)-3.88%
ROA(5y)3.21%
ROE(3y)-6.46%
ROE(5y)4.15%
ROIC(3y)N/A
ROIC(5y)N/A
CANG Yearly ROA, ROE, ROICCANG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

CANG has a Profit Margin (0.17%) which is in line with its industry peers.
CANG's Profit Margin has improved in the last couple of years.
In the last couple of years the Operating Margin of CANG has declined.
CANG has a worse Gross Margin (13.27%) than 87.60% of its industry peers.
CANG's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 0.17%
GM 13.27%
OM growth 3Y61.58%
OM growth 5Y-5.43%
PM growth 3YN/A
PM growth 5Y6.57%
GM growth 3Y-7.64%
GM growth 5Y-20.99%
CANG Yearly Profit, Operating, Gross MarginsCANG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 150

More info and screens

3

2. Health

2.1 Basic Checks

CANG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CANG remains at a similar level compared to 1 year ago.
CANG has less shares outstanding than it did 5 years ago.
CANG has a worse debt/assets ratio than last year.
CANG Yearly Shares OutstandingCANG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CANG Yearly Total Debt VS Total AssetsCANG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

CANG has an Altman-Z score of 1.01. This is a bad value and indicates that CANG is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CANG (1.01) is worse than 70.25% of its industry peers.
A Debt/Equity ratio of 0.20 indicates that CANG is not too dependend on debt financing.
CANG's Debt to Equity ratio of 0.20 is fine compared to the rest of the industry. CANG outperforms 62.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z 1.01
ROIC/WACCN/A
WACC9.5%
CANG Yearly LT Debt VS Equity VS FCFCANG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B

2.3 Liquidity

CANG has a Current Ratio of 1.41. This is a normal value and indicates that CANG is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.41, CANG perfoms like the industry average, outperforming 57.02% of the companies in the same industry.
A Quick Ratio of 1.41 indicates that CANG should not have too much problems paying its short term obligations.
With an excellent Quick ratio value of 1.41, CANG belongs to the best of the industry, outperforming 85.12% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.41
Quick Ratio 1.41
CANG Yearly Current Assets VS Current LiabilitesCANG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for CANG have decreased strongly by -100.27% in the last year.
CANG shows a strong growth in Revenue. In the last year, the Revenue has grown by 91.08%.
Measured over the past years, CANG shows a very strong growth in Revenue. The Revenue has been growing by 55.29% on average per year.
EPS 1Y (TTM)-100.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)91.08%
Revenue growth 3Y53.17%
Revenue growth 5Y55.29%
Sales Q2Q%2126.15%

3.2 Future

Based on estimates for the next years, CANG will show a very strong growth in Earnings Per Share. The EPS will grow by 90.44% on average per year.
CANG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.76% yearly.
EPS Next Y-1100%
EPS Next 2Y-199.67%
EPS Next 3Y81.71%
EPS Next 5Y90.44%
Revenue Next Year-49.58%
Revenue Next 2Y-21.02%
Revenue Next 3Y14.29%
Revenue Next 5Y7.76%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CANG Yearly Revenue VS EstimatesCANG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2B 4B 6B
CANG Yearly EPS VS EstimatesCANG Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 5 -5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 63.57, CANG can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of CANG is on the same level as its industry peers.
The average S&P500 Price/Earnings ratio is at 27.38. CANG is valued rather expensively when compared to this.
CANG is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 63.57
Fwd PE N/A
CANG Price Earnings VS Forward Price EarningsCANG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

CANG's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. CANG is more expensive than 70.25% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 116.54
CANG Per share dataCANG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4 5

4.3 Compensation for Growth

A more expensive valuation may be justified as CANG's earnings are expected to grow with 81.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-199.67%
EPS Next 3Y81.71%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CANG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CANGO INC/KY - ADR

NYSE:CANG (9/19/2025, 8:04:00 PM)

After market: 4.45 0 (0%)

4.45

-0.17 (-3.68%)

Chartmill FA Rating
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)09-04 2025-09-04/amc
Earnings (Next)11-03 2025-11-03
Inst Owners9.53%
Inst Owner Change1.56%
Ins Owners0.97%
Ins Owner ChangeN/A
Market Cap461.86M
Analysts82.86
Price Target8.16 (83.37%)
Short Float %3.9%
Short Ratio2.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)166.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-147.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.8%
Revenue NY rev (1m)7.92%
Revenue NY rev (3m)15.62%
Valuation
Industry RankSector Rank
PE 63.57
Fwd PE N/A
P/S 1.83
P/FCF N/A
P/OCF N/A
P/B 0.85
P/tB 0.86
EV/EBITDA 116.54
EPS(TTM)0.07
EY1.57%
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.43
BVpS5.24
TBVpS5.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.04%
ROE 0.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 0.17%
GM 13.27%
FCFM N/A
ROA(3y)-3.88%
ROA(5y)3.21%
ROE(3y)-6.46%
ROE(5y)4.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y61.58%
OM growth 5Y-5.43%
PM growth 3YN/A
PM growth 5Y6.57%
GM growth 3Y-7.64%
GM growth 5Y-20.99%
F-ScoreN/A
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA 28.01
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.41
Quick Ratio 1.41
Altman-Z 1.01
F-ScoreN/A
WACC9.5%
ROIC/WACCN/A
Cap/Depr(3y)348.58%
Cap/Depr(5y)264.99%
Cap/Sales(3y)38.63%
Cap/Sales(5y)23.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-100.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-1100%
EPS Next 2Y-199.67%
EPS Next 3Y81.71%
EPS Next 5Y90.44%
Revenue 1Y (TTM)91.08%
Revenue growth 3Y53.17%
Revenue growth 5Y55.29%
Sales Q2Q%2126.15%
Revenue Next Year-49.58%
Revenue Next 2Y-21.02%
Revenue Next 3Y14.29%
Revenue Next 5Y7.76%
EBIT growth 1Y-162.18%
EBIT growth 3Y-4.73%
EBIT growth 5Y-15.84%
EBIT Next Year29.49%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-220.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-130.21%
OCF growth 3YN/A
OCF growth 5YN/A